{"search_session":{},"preferences":{"l":"ar","queryLanguage":"ar"},"patentId":"116-468-163-815-774","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"116-468-163-815-774"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10710,"type":"PATENT","title":"University of Colorado Boulder Patent Portforlio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7179,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8227,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:\"University Colorado\" \"univ* Colorado\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4836
Search Applicants and Owners separately: colorado state uni*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1775
Search Applicants and Owners separately:\"University Colorado\" \"univ* Colorado\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4836
Search Applicants and Owners separately: colorado state uni*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1775
wherein\n
R1 is hydrogen or C1-6alkyl;\n
is a single bond or double bond;\n
Q1 is N or CH;\n
R2 is selected from hydrogen and C1-6 alkylene, wherein one carbon unit of said alkylene is optionally replaced with —O—, —S—, —SO—, —SO2—, —NRa—, or —CO—; wherein Ra is hydrogen or C1-6 alkyl; and\n
R3 is hydrogen or an optionally substituted 5-membered heteroaryl ring; wherein the heteroaryl ring is optionally substituted with C1-6alkyl;\n
or pharmaceutically acceptable salts thereof."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the vaccine comprises live whole virus, killed whole virus, attenuated whole virus, killed bacteria, attenuated bacteria, a virus-like particle, a bacterial, viral, or parasite protein, a recombinant protein, or a peptide."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) and the vaccine are present in a single pharmaceutical composition."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is present in a first pharmaceutical composition and wherein the vaccine is present in a second pharmaceutical composition."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is a compound of Formula (II):\n
wherein\n
R1 is hydrogen or C1-6 alkyl;\n
is a single bond or double bond;\n
Q1 is N or CH; and\n
R4 is an optionally substituted 5-membered heteroaryl ring; wherein the heteroaryl ring is optionally substituted with C1-6alkyl;\n
or pharmaceutically acceptable salts thereof."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is a compound of Formula (III):\n
wherein\n
is a single bond or double bond;\n
Q1 is N or CH; and\n
R4 is an optionally substituted 5-membered heteroaryl ring; wherein the heteroaryl ring is optionally substituted with C1-6alkyl;\n
or pharmaceutically acceptable salts thereof."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is a compound of Formula (IV):\n
wherein\n
R1 is hydrogen or C1-6 alkyl;\n
is a single bond or double bond;\n
Q1 is N or CH; and\n
R4 is selected from\n\n
or pharmaceutically acceptable salts thereof."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is a compound of Formula (V):\n
wherein\n
is a single bond or double bond;\n
Q1 is N or CH; and\n\n
R4 is selected from\n
or pharmaceutically acceptable salts thereof."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is Ondansetron."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the Ondansetron is administered at a dosage of less than 12 mg."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the individual has not taken Ondansetron for the treatment of irritable bowel syndrome (IBS), post-operative nausea and vomiting (PONY), radiation-induced nausea and vomiting (RINV), or chemotherapy-induced nausea and vomiting (CINV)."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the individual does not have a detectable level of Ondansetron in their blood or urine prior to administration of the Ondansetron in conjunction with the vaccine."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound of Formula (I) is Alosetron."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the Alosetron is administered at a dosage of less than 0.5 mg."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the individual has not taken Alosetron for the treatment of irritable bowel syndrome (IBS), post-operative nausea and vomiting (PONY), radiation-induced nausea and vomiting (RINV), or chemotherapy-induced nausea and vomiting (CINV)."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein the individual does not have a detectable level of Alosetron in their blood or urine prior to administration of the Alosetron in conjunction with the vaccine."],"number":16,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}